Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Fund Details
Upturn AI Summary
Virtus LifeSci Biotech Products ETF(BBP)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for BBP
10/28/2026: BBP (2-star) is currently NOT-A-BUY. Pass it for now.
The Virtus LifeSci Biotech Products ETF (BBP) offers targeted exposure to biotechnology companies that have successfully secured FDA product approvals, distinguishing it from clinical-stage-heavy funds. Its main strength lies in its focus on revenue-generating biotech firms, though investors should note its higher expense ratio and lower liquidity relative to broad-market competitors. It functions primarily as a thematic, high-growth holding within a diversified portfolio. Key risks include sector concentration, regulatory pricing pressure, and potential patent expirations. It is most suitable for growth-focused investors who can tolerate significant volatility and perform regular monitoring of regulatory and M&A trends.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The biotech sector is characterized by high potential growth driven by product innovation and commercial scaling. |
| Momentum investor | Mixed fit | The fund can experience significant momentum-driven swings, though it requires a positive sector signal to manage inherent volatility. |
| Value investor | Weak fit | Biotech stocks often trade at high valuations based on future expectations, which does not typically align with traditional value metrics. |
| Dividend/Income investor | Weak fit | Biotech companies in this fund typically reinvest cash flow into R&D rather than paying dividends. |
| Low-risk investor | Weak fit | This fund is inherently volatile and unsuitable for investors prioritizing capital preservation. |
Investor Profile
Ideal Investor Profile
The ideal investor is an experienced participant comfortable with sector-specific volatility and high-growth, high-risk assets.
Suitability
Best suited for growth-oriented, long-term investors who understand biotech risks and want to bet on companies with proven, FDA-approved products.
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Volatility | High | The biotech sector is prone to extreme price fluctuations based on regulatory news and clinical data. |
| Market risk | Medium / high | General market downturns often disproportionately affect speculative growth sectors like biotech. |
| Concentration | High | The fund focuses on a narrow sub-industry of the healthcare sector. |
| Tracking/expense | Medium | The higher expense ratio can weigh on total returns over extended holding periods. |
| Liquidity | Medium | Lower average volume can make entering or exiting large positions more costly. |
| Business/sector quality | Medium / high | Reliance on specific FDA product approvals introduces significant binary business risks. |
Risk Analysis
Volatility
High; the fund experiences significant swings tied to sector-specific regulatory news.
Market Risk
Substantial; exposed to high-beta assets that react sharply to broader market volatility.
What the ETF Owns
| Exposure Type | Exposure | Weight (%) | Retail Investor Read |
|---|---|---|---|
| Industry | Biotechnology (FDA-approved product focus) | 98 | This sector allocation focuses on established biotech firms with commercialized revenue rather than purely clinical-stage companies. |
| Cash/collateral | Cash and Cash Equivalents | 2 | Small residual cash position held for operational liquidity and trade settlement. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Smooth
The stock has moved along a generally orderly path with only modest fluctuations.
Analysis of Past Performance
Type ETF | Historic Profit 69.81% | Avg. Invested days 101 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  5.0 | ETF Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/28/2026 |
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.